Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Lichen Planopilaris

NCT07532603 is registered in ClinicalTrials.gov with Priovant Therapeutics, Inc. as lead sponsor.

NCT NCT07532603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07532603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Lichen Planopilaris
Lead sponsor
Priovant Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
March 19, 2026
Completion date
July 31, 2029
Enrollment
342 (estimated)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

lichen planopilaris